Company intelligence / Profile preview

Bedfont Scientific

Harrietsham, Kent, United Kingdom

Ownership: Private
Employees: ~41
Development stage: Other

Overview

Bedfont Scientific manufactures, markets, and exports non-invasive breath and gas analysis devices used for medical diagnosis and monitoring. Key products include FeNO for asthma, hydrogen/methane for GI disorders, CO for poisoning and smoking cessation, and PEMF for wellness. NObreath FeNO is FDA-cleared. The company was acquired (majority stake) by Keensight Capital in 2024 and is actively expanding.

Therapeutic areas: GastroenterologyPulmonologyPsychiatry
Modalities: DeviceNon-pharmacological therapyMagnetic therapy (PEMF)
Industry: Physiological Monitoring

Partnerships

Tebaba Medical Services (Middle East/Africa distributor)Praxair (NOxBOX range sale, 2016)

Beyond the preview

Go deeper on Bedfont Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bedfont Scientific.

Explore the full profile